Peggy Lillis Foundation’s annual Summit has often created the opportunity for C. diff advocates to connect with clinicians, researchers, and industry representatives. We feared that taking it virtual would hinder those connections. Turns out we needn’t have worried. Among the connections made at this year’s Summit was one between Idaho-based …
April 2020 marked a decade since we lost Peggy Lillis to a community-acquired C. difficile infection and founded the Peggy Lillis Foundation (PLF) to combat this disease. It also marked our fifth National C. diff Advocacy Summit. Initially planned to once again be held in Washington, DC, due to COVID-19 PLF …
Fecal microbiota transplant (FMT) as a treatment for C. difficile infections has skyrocketed over the past decade. While it has saved tens of thousands of lives, FMT remains controversial and the Food and Drug Administration (FDA) has been slow to formalize its regulatory status. This has left doctors, scientists, drug …
The Food and Drug Administration (FDA) issued a Safety Alert today Regarding Use of Fecal Microbiota for Transplantation and Additional Safety Protections Pertaining to COVID-19. According to the alert, “FDA is informing health care providers and patients of the potential risk of transmission of SARS-CoV-2 virus by the use of fecal …
On March 12, the Food and Drug Administration (FDA) issued a safety alert that eight patients were infected following fecal microbiota transplants (FMT) using material from a company which was later confirmed to be OpenBiome, an independent stool bank. Two of the patients subsequently died. FDA did not name OpenBiome …
